6
Views
26
CrossRef citations to date
0
Altmetric
Original Article

The effect on HDL cholesterol of oxprenolol and atenolol

, , , , &
Pages 449-453 | Received 26 Jan 1982, Accepted 26 Apr 1982, Published online: 17 Mar 2010

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Murray Esler, Sverre E. Kjeldsen, Atul Pathak, Guido Grassi, Reinhold Kreutz & Giuseppe Mancia. (2022) Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified. Blood Pressure 31:1, pages 210-224.
Read now
Sverre Erik Kjeldsen, Ivar Eide, Paul Leren & Olav P. Foss. (1983) Effects of posture on serum cholesterol fractions, cholesterol ratio and triglycerides. Scandinavian Journal of Clinical and Laboratory Investigation 43:2, pages 119-121.
Read now

Articles from other publishers (24)

Márcia MS Bernik, Joel C Heimann, Edna R Nakandakare, Patrícia M Cazita, Valéria S Nunes, Jussara C Rocha, Mônica QTS Neves & Eder CR Quintão. (2005) Effects of hydrochlorothiazide and propranolol treatment on chylomicron metabolism in hypertensive subjects. Canadian Journal of Physiology and Pharmacology 83:7, pages 617-623.
Crossref
M.C. Houston, L. Olafsson & M.C. Burger. (2016) Effects of Nifedipine GITS and Atenolol Monotherapy on Serum Lipids, Blood Pressure, Heart Rate, and Weight in Mild to Moderate Hypertension. Angiology 42:9, pages 681-690.
Crossref
Paolo Ferrari, Johan Rosman & Peter Weidmann. (1991) Antihypertensive agents, serum lipoproteins and glucose metabolism. The American Journal of Cardiology 67:10, pages B26-B35.
Crossref
P. Smith, I. Seljeflot & T. Opstad. (1990) Withdrawal of chronic beta- adrenoceptorblockade: Effects on haemodynamics, blood lipids and haemostatic variables. European Journal of Clinical Pharmacology 39:1, pages 81-82.
Crossref
Mark C Houston, Candice Burger, James Taylor Hays, John Nadeau, Larry Swift, Charles A Bradley & Laurie Olafsson. (1990) The effects of clonidine hydrochloride versus atenolol monotherapy on serum lipids, lipid subfractions, and apolipoproteins in mild hypertension. American Heart Journal 120:1, pages 172-179.
Crossref
Stanley H. Taylor & Richard H. GrimmJr.Jr.. (1990) New developments in the role of α1-adrenergic receptors in cardiovascular disease. American Heart Journal 119:3, pages 655-662.
Crossref
Richard H. GrimmJr.Jr. & John M. Flack. (1989) Management of hypertension. The American Journal of Medicine 87:2, pages S62-S65.
Crossref
Mark C. Houston. (1989) New insights and new approaches for the treatment of essential hypertension: Selection of therapy based on coronary heart disease risk factor analysis, hemodynamic profiles, quality of life, and subsets of hypertension. American Heart Journal 117:4, pages 911-951.
Crossref
Sverre E. Kjeldsen, Knut Lande, Knut Gjesdal, Paul Leren & Ivar K. Eide. (2009) Plasma Adrenaline: Relations to Blood Pressure, Blood Platelet Function and Blood Lipids in Essential Hypertension. Pharmacology & Toxicology 63:s1, pages 35-37.
Crossref
Inger Nafstad, Sverre Tollersrud, Karin Eriksen, Anders Helgeland, Lars Åge Solberg, Jan Bredesen & Ola Dale. (1988) The influence of atenolol and prazosin on serum lipids and atherosclerosis in minipigs fed a hyperlipidemic diet. General Pharmacology: The Vascular System 19:5, pages 719-724.
Crossref
H. Wolinsky. (2009) The effects of beta‐adrenergic blocking agents on blood lipid levels. Clinical Cardiology 10:10, pages 561-566.
Crossref
Norman E. Miller. (1987) Effects of adrenoceptor-blocking drugs on plasma lipoprotein concentrations. The American Journal of Cardiology 60:9, pages 17-23.
Crossref
S. E. KJELDSEN, I. TAYLOR, A. WESTHEIM, O. P. FOSS, P. LEREN & I. K. EIDE. (2012) Severe sodium restriction alone and with potassium supplementation does not alter blood lipoproteins in essential hypertension. European Journal of Clinical Investigation 17:2, pages 182-186.
Crossref
Paul Leren. (1987) Comparison of effects on lipid metabolism of antihypertensive drugs with alpha- and beta-adrenergic antagonist properties. The American Journal of Medicine 82:1, pages 31-35.
Crossref
Jukka T. Salonen, Esko Taskinen, Riitta Salonen, Kari Seppänen, Juha Venäläinen & Rainer Rauramaa. (1986) Effects of bevantolol and atenolol on symptoms, exercise tolerance and metabolic risk factors in angina pectoris. The American Journal of Cardiology 58:12, pages E35-E40.
Crossref
H. Arnesen, P. Smith & E.B. Aspelund. (1986) Changes in fibrinolytic capacity and lipoprotein pattern during long-term treatment with warfarin. Thrombosis Research 44:2, pages 229-233.
Crossref
Stephen W. MacMahon & Graham J. Macdonald. (1986) Antihypertensive treatment and plasma lipoprotein levels: The associations in data from a population study. The American Journal of Medicine 80:2, pages 40-47.
Crossref
Paul Leren & Anders Helgeland. (1986) Coronary heart disease and treatment of hypertension some Oslo study data. The American Journal of Medicine 80:2, pages 3-6.
Crossref
S W MacMahon, G J Macdonald & R B Blacket. (1985) Plasma lipoprotein levels in treated and untreated hypertensive men and women. The National Heart Foundation of Australia Risk Factor Prevalence Study.. Arteriosclerosis: An Official Journal of the American Heart Association, Inc. 5:4, pages 391-396.
Crossref
Paul Leren. (2009) The Hypertension‐CHD Dilemma. Acta Medica Scandinavica 217:2, pages 145-147.
Crossref
Kees Schoonderwoerd, Willem C. Hülsmann & Hans Jansen. (1984) Regulation of liver lipase. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 795:3, pages 481-486.
Crossref
Anders Helgeland, Paul Leren, Sverre Kjeldsen, Ivar Eide & Olav Per Foss. (2009) Changes in the lipoprotein profile during antihypertensive therapy. Acta Pharmacologica et Toxicologica 54:s1, pages 75-77.
Crossref
W. Krone, D. M?ller-Wieland & H. Greten. (1984) Antihypertensive Therapie und FettstoffwechselAntihypertensive therapy and lipid metabolism. Klinische Wochenschrift 62:5, pages 193-202.
Crossref
Paul Leren. (1984) Effect of alpha- and beta-blocker therapy on blood lipids: European experience. The American Journal of Medicine 76:2, pages 67-71.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.